HLA-A and cancer: In accordance, mutations in the canonical HLA class I pathway (HLA-A/B/C) and its associated components in patients with cancer have been previously described, e.g. transporter associated with Antigen Processing 1/2 (TAP1/2), latent membrane protein 2/7 (LMP2/7) and β2-microglobulin (151, 159–164).